News

IDT Australia Executes API Development Agreement

• API Development Agreement executed with The State Government of Victoria • Total consideration over AUD 2,000,000 over the twelve month term of the project Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX:IDT) announces it…

AdAlta appoints Dr Dallas Hartman as Chief Operating Officer

AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the appointment of experienced executive, Dr Dallas Hartman to the role of Chief Operating Officer. Dr Hartman will bring…

Patrys and Garvan Institute of Medical Research Awarded Grant

Patrys Limited (ASX: PAB), a clinical stage biotechnology company and Sydney’s Garvan Institute of Medical Research (Garvan) have recently finalized the terms of a Federal Government Innovation Connections grant to support research within the PATDX1 program. The Garvan…

New US patent for Patrys PAT-LM1

Patrys (ASX:PAB), a clinical stage biotechnology company, has been granted a US patent for its anti-cancer pre-clinical candidate PAT-LM1. The US Patent Office has issued correspondence confirming the grant of a key patent in the PAT-LM1 family, patent…

Universal Biosensors receives $7.5M under the R&D Tax Incentive

Universal Biosensors (ASX:UBI) today announced it has received $7.5M in cash under the R&D Tax Incentive for the 2016 financial year. The R&D Tax Incentive is an Australian Government program developed to assist eligible businesses recover some of…

CLOSED Scientific Customer Service & Applications Sales Support | VIC

• New & innovative automation system • World first technology • Flexible full time or part time Our client’s mission is to bring innovative scientific products to enhance and strengthen their customers business and research. Their product range…

Medical Device Industry Sign Historic Agreement to Reduce Health Fund Premiums

The Medical Technology Association of Australia (MTAA) has signed a four-year Agreement with the Federal Government which will deliver certainty and stability to the industry and will help lower Private Health Insurance (PHI) premiums for Australians. The Agreement,…

GKC names John Schellhorn new President and CEO

GKC announced today that it has appointed John Schellhorn as its new President and CEO. Schellhorn will also be joining the company’s Board of Directors. Schellhorn joins GKC with a proven track record to spearhead the company’s accelerated…

Starpharma and Peter Mac Cancer Centre awarded DEP® Grant

Starpharma (ASX: SPL, OTCQX: SPHRY) and Peter MacCallum Cancer Centre (Peter Mac) have been awarded a further Federal Government Innovation Connections grant to support innovative research within Starpharma’s DEP® oncology program. Starpharma’s proprietary DEP® dendrimer platform improves efficacy…

LBT Receives $4.2 Million in R&D Incentives

Australian medical technology company LBT Innovations Limited (ASX:LBT) has received an R&D Incentive, net of income tax payable, of $3.98 Million for the financial year ended 30 June 2017. In addition, LBT has also received $0.22 Million for…

BioMelbourne Network submission to the Policy Consultation Paper – Visa Simplification: Transforming Australia’s Visa System

“Australia’s visa system must remain globally competitive to attract talent to build future industries and transition to a knowledge-led economy” Health is a global market and access to global talent is critical for healthcare innovation. Companies need to…

Starpharma – DEP® docetaxel positive phase 1 results; phase 2 commences

DEP® docetaxel phase 1 trial successfully completed with phase 2 to commence immediately DEP® docetaxel patients had no reports of neutropenia, a life-threatening toxicity seen in virtually all patients treated with conventional docetaxel formulations (e.g. Taxotere®)   Encouraging signs of efficacy observed…

Home

News & opinion

Member Directory

Events